# Correction: Disulfiram as an anti-inflammatory agent: mechanisms, nano-delivery strategies, and applications in non-oncologic diseases

**Authors:** Qiwen Jiang, Mengni Jiang, Yanwei Lv, Xinyuan Zhang, Shige Wang, Jiulong Zhao

PMC · DOI: 10.1039/d6ra90023b · RSC Advances · 2026-02-19

## TL;DR

This paper corrects a previously published article on disulfiram's anti-inflammatory properties and its use in non-cancer diseases.

## Contribution

The paper provides corrections to prior work, ensuring accuracy in the mechanisms and applications of disulfiram.

## Key findings

- Errors in the original paper have been identified and corrected.
- The revised information maintains the focus on disulfiram's anti-inflammatory mechanisms and nano-delivery strategies.

## Abstract

Correction for ‘Disulfiram as an anti-inflammatory agent: mechanisms, nano-delivery strategies, and applications in non-oncologic diseases’ by Qiwen Jiang et al., RSC Adv., 2025, 15, 36344–36364, https://doi.org/10.1039/D5RA04662A.

## Linked entities

- **Chemicals:** Disulfiram (PubChem CID 3117)

## Full-text entities

- **Genes:** GSDMD (gasdermin D) [NCBI Gene 79792] {aka DF5L, DFNA5L, FKSG10, GSDMDC1}
- **Diseases:** pyroptosis.12 (MESH:C564486), oncologic diseases (MESH:D000072716), inflammatory (MESH:D007249)
- **Chemicals:** copper (MESH:D003300), Disulfiram (MESH:D004221), DSF (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12917488/full.md

---
Source: https://tomesphere.com/paper/PMC12917488